Mylan Sees COVID-19 Impact On Sales

Also Exploring International Listings For Viatris After Upjohn Merger

11 Aug 2020

Mylan has seen its second-quarter performance echo that of its industry peers, with a lift provided by COVID-19 related demand in the first three months of the year balanced out by declines in the second quarter of 2020.

Roller coaster — A rise in Q1 has been followed by a corresponding drop in Q2 • Source: Shutterstock

Mylan has seen its sales slump in Europe and in the rest of the world in the second quarter of 2020 due to COVID-19, balancing out the additional demand that had been seen by the company in the first quarter. (Also see "Mylan Delays Restructuring Amid COVID-19" - Generics Bulletin, 14 May, 2020.)

In North America, higher volumes of products such as Mylan’s Wixela Inhub (fluticasone/salmeterol) rival to Advair Diskus and sales from...